Serum aminotransferase activity in patients of epilepsy and mania taking sodium valproate.

  • Asha Khubchandani
  • Janki Jadav
  • Gagandeep Sidhu
  • Viral Solanki
  • Sagar Gangwani
  • Meghna Solanki
Keywords: Aminotransferase, Epilepsy, Mania, Sodium Valproate


Background: Our aim is to study the serum aminotransferase activity in patients of epilepsy and mania taking sodium valproate.  Sodium valproate is a common drug to be prescribed to the patients of epilepsy and mania. Aminotransferase, both AST (Aspartate amino transferase) and ALT (Alanine amino transferase) is an accepted marker for any liver injury.Methods:  Serum sample of fifty patients of known cases of epilepsy and mania, who were on sodium valproate since at least 3 month and fifty normal subjects were taken. Serum aminotransferase level (both AST & ALT) were estimated by colorimetric method in fully automated Erba XL-640 Analyser.Results: The level of aminotransferase enzymes were  increased in patients of epilepsy and mania after administration of sodium valproate and elevation was highly significant  as compared to the normal subjects (p value <0.05).Conclusion: From our study it is concluded that there is a need for monitoring serum aminotransferase level in patients receiving sodium valproate.


1. Nikalje A, Ghodke M, Girbane A. GABA modulating agents: a brief review. Asian Journal of Biological Sciences 2011; 4: 201-20.
2. Ahmad M. Epilepsy: stigma and management. Current Research in Neuroscience 2011;201:1-14.
3. Arroyo S, de la Morena A. Life-threatening adverse events of antiepileptic drugs. Epilepsy Research 2001;47:155-74
4. Ahmed SN, Siddiqi ZA. Antiepileptic drugs and liver disease. Seizure 2006; 15: 156-64.
5. Lee WM. Drug-induced hepatotoxicity. New England Journal of Medicine 2003; 349:474-85.
6. Bergmeyer HU, Horder M, Rej R. Clin. Chem. Clin. Biochem. 1986;24:481-95.
7. Henry RJ, Cannon DC, Winkerman JW. Clinical Chemistry Principle and Tech-niques, 2nd. Edn. Hagerstown MD., harper and Raw. 1974
8. Teitz NW. Clinical Guide to Laboratory tests. 3rd ed, W.B. Saunders. Philadelphia USA, 1995.
9. Verma NP, Haidukewych D. Differential but infrequent alterations of hepatic en-zyme levels and thyroid hormone levels by anticonvulsant drugs. Archives of Neurology 1994;51:381-4.
10. Spiller HA, Spiller H, Krenzelok EP, Klein-Schwartz W, Winter ML, Weber JA, et al. Multicenter case series of valproic acid ingestion: serum concentrations and toxicity. Clinical Toxicology 2000; 38: 755-60.
11. Sussman NM. Hepatotoxicity of valproic acid. Neurology 1979;29:601.
12. Felker BL, Sloan KL, Dominitz JA, Barnes RF. The safety of valproic acid use for patients with hepatitis c infection. American Journal of Psychatry 2003;160:174-8.
13. Willmore LJ, Wilder BJ, Bruni J, Villarreal HJ. Effect of valproic acid on hepatic function. Neurology 1978;28: 961-4.
14. Boelsterli UA, Lim PLK. Mitochondrial abnormalities: a link to idiosyncratic drug hepatotoxicity. Toxicology. 2007; 220: 92 -107.
Original Article

Most read articles by the same author(s)